Literature DB >> 7840585

Intracellular and extracellular penetration of azithromycin into inflammatory and noninflammatory blister fluid.

C D Freeman1, C H Nightingale, D P Nicolau, P P Belliveau, M A Banevicius, R Quintiliani.   

Abstract

The penetration of azithromycin into the blister fluids of six volunteers was analyzed after a 5-day regimen (total of 1.5 g). Differences in drug concentrations in a paper disk and serum and in the mass of azithromycin from inflammatory blister chamber leukocytes and noninflammatory blister chamber leukocytes were significant (P < 0.05).

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7840585      PMCID： PMC284759          DOI： 10.1128/AAC.38.10.2449

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  Critically ill anergic patients demonstrate polymorphonuclear neutrophil activation in the intravascular compartment with decreased cell delivery to inflammatory focci.

Authors:  J M Tellado; N V Christou
Journal:  J Leukoc Biol       Date:  1991-12       Impact factor: 4.962

2.  The pharmacokinetics and inflammatory fluid penetration of orally administered azithromycin.

Authors:  M A Cooper; K Nye; J M Andrews; R Wise
Journal:  J Antimicrob Chemother       Date:  1990-10       Impact factor: 5.790

3.  Stimulation with cytokines enhances penetration of azithromycin into human macrophages.

Authors:  L E Bermudez; C Inderlied; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

4.  Neutrophil studies in psoriatics: in vivo migration, phagocytosis and bacterial killing.

Authors:  L Dubertret; C Lebreton; R Touraine
Journal:  J Invest Dermatol       Date:  1982-08       Impact factor: 8.551

5.  The pharmacokinetics of azithromycin in human serum and tissues.

Authors:  G Foulds; R M Shepard; R B Johnson
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

6.  Intracellular accumulation of azithromycin by cultured human fibroblasts.

Authors:  R P Gladue; M E Snider
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

7.  In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection.

Authors:  R P Gladue; G M Bright; R E Isaacson; M F Newborg
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

8.  Dynamics of the cellular and humoral components of the inflammatory response elicited in skin blisters in humans.

Authors:  D B Kuhns; E DeCarlo; D M Hawk; J I Gallin
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

9.  Human leucocyte migration: studies with an improved skin chamber technique.

Authors:  K B Hellum; C O Solberg
Journal:  Acta Pathol Microbiol Scand C       Date:  1977-12

10.  In vitro and in vivo intraleukocytic accumulation of azithromycin (CP-62, 993) and its influence on ex vivo leukocyte chemiluminescence.

Authors:  M Bonnet; P Van der Auwera
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191
View more
  10 in total

Review 1.  Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue.

Authors:  Markus Müller; Amparo dela Peña; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

2.  Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.

Authors:  Songmao Zheng; Peter Matzneller; Markus Zeitlinger; Stephan Schmidt
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

3.  Bronchopulmonary pharmacokinetics of clarithromycin and azithromycin.

Authors:  A D Kashuba; G W Amsden
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

4.  Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy.

Authors:  P Matzneller; S Krasniqi; M Kinzig; F Sörgel; S Hüttner; E Lackner; M Müller; M Zeitlinger
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

5.  Transport of Azithromycin into Extravascular Space in Rats.

Authors:  Shinji Kobuchi; Miki Aoki; Chiaki Inoue; Hiroyuki Murakami; Akiko Kuwahara; Tsutomu Nakamura; Hiroyuki Yasui; Yukako Ito; Kanji Takada; Toshiyuki Sakaeda
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

6.  Development of a population pharmacokinetic model to describe azithromycin whole-blood and plasma concentrations over time in healthy subjects.

Authors:  T Pene Dumitrescu; T Anic-Milic; K Oreskovic; J Padovan; K L R Brouwer; P Zuo; V D Schmith
Journal:  Antimicrob Agents Chemother       Date:  2013-04-29       Impact factor: 5.191

Review 7.  Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.

Authors:  Markus Zeitlinger; Claudia Christina Wagner; Birgit Heinisch
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

8.  Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults.

Authors:  Keith A Rodvold; Larry H Danziger; Mark H Gotfried
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

9.  Pharmacokinetics of Oral Azithromycin in Serum, Urine, Polymorphonuclear Leucocytes and Inflammatory vs Non-Inflammatory Skin Blisters in Healthy Volunteers.

Authors:  C H Ballow; G W Amsden; V S Highet; A Forrest
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

10.  Pharmacokinetics of Macrolide Antibiotics and Transport into the Interstitial Fluid: Comparison among Erythromycin, Clarithromycin, and Azithromycin.

Authors:  Shinji Kobuchi; Teruhiko Kabata; Koki Maeda; Yukako Ito; Toshiyuki Sakaeda
Journal:  Antibiotics (Basel)       Date:  2020-04-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.